𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A comprehensive genetic study of the proteasomal subunit S6 ATPase in German Parkinson’s disease patients

✍ Scribed by Claudia Wahl; Sabine Kautzmann; Guido Krebiehl; Karsten Strauss; Dirk Woitalla; Thomas Müller; Peter Bauer; Olaf Riess; Rejko Krüger

Publisher
Springer
Year
2008
Tongue
English
Weight
405 KB
Volume
115
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genetic association study of the P-type
Genetic association study of the P-type ATPase ATP13A2 in late-onset Parkinson's disease
✍ Aleksandar Rakovic; Barbara Stiller; Ana Djarmati; Antonia Flaquer; Jan Freudenb 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 905 KB

## Abstract A role of __ATP13A2__ in early‐onset Parkinsonism (EOP) has been proposed. Conversely, the contribution of this ATPase to late‐onset Parkinson's disease (PD) remains unexplored. We therefore conducted a case–control association study in this age‐of‐onset group with PD. The initial sampl

Localized proton NMR spectroscopy in the
Localized proton NMR spectroscopy in the striatum of patients with idiopathic parkinson's disease: a multicenter pilot study
✍ Barbara A. Holshouser; Markku Komu; Harald E. Möller; Jan Zijlmans; Heinrich Kol 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 641 KB

Single voxel proton MRS was used to study brain metabolism in the striatum of patients diagnosed with idiopathic Parkinson's disease (PD). Peak metabolite ratios in long echo time spectra were evaluated in 151 patient spectra and 97 age-matched control spectra collected at four participating institu

Efficacy of piribedil as early combinati
Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study
✍ Marc Ziegler; Alexandre Castro-Caldas; Susanna Del Signore; Olivier Rascol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 775 KB

## Abstract Piribedil is a non‐ergot D2/D3 agonist with a significant antagonist action on α2A and α2C adrenergic receptor subtypes. This double‐blind placebo‐controlled study was undertaken to confirm the efficacy of 150 mg/day piribedil po in improving motor symptoms of idiopathic Parkinson's dis

Ropinirole in the treatment of early Par
Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
✍ Dr. Olivier Rascol; David J. Brooks; Ehrout R. Brunt; Amos D. Korczyn; Warner H. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 785 KB

The efficacies of ropinirole and levodopa were compared after 6 months of treatment in a planned interim analysis of a 5-year, double-blind, randomized, multicenter study of patients with early Parkinson's disease requiring dopaminergic therapy. The percentage of improvement in the Unified Parkinson

Ropinirole versus bromocriptine in the t
Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study
✍ Prof. Amos D. Korczyn; David J. Brooks; Ehrout R. Brunt; Warner H. Poewe; Olivie 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 705 KB

We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3-year, double-blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or wit